12 
pennit requests for lowering of ccxitaimnent for specific experiments in 
this class to be approved by ORDA. RAC review would not be required. 
Dr. Mason seccxided the substitute motion. 
Dr. Brill said that the investigator would be most knowledgeable about 
the organism. He questioned whether ORDA review should be required. 
Dr. Cairpbell spoke in support of Dr. Brill's motion. He felt the restric- 
tions placed on recombinant ENA research were discouraging innovation. 
Mr. Thornton called the vote on Dr. Gottesman's substitute motion. The 
RAC voted against Dr. Gottesman's motion by a vote of six in favor, eight 
c(%>osed, and two abstentions. 
Dr. Nightingale suggested that "ncxpathogenic" is too absolute a term; 
certain organisms normally not pathogenic can cause disease in compromised 
hosts. Other menfcers concurred. 
Dr. Baltimore said the committee, in evaluating this proposal, should 
face the basic questicxi of vhether recombinant DNA technology is likely 
to produce an organism more pathogenic than the original donor organisms. 
Dr. Levine said that while nany members of the committee feel it is 
exceedingly unlikely that recombinant ENA technology will create a new 
pathogen of clinical significance, disparities could arise among insti- 
tutions concerning vhether a given organism is, or is not, a pathogen 
under Dr. Brill's proposal. 
Mr. Thornton then called the vote on Dr. Brill's amended proposal. By a 
vote of nine in favor, ei^t opposed, and three abstentions, the RAC 
acc^ted Dr. Brill's proposal. Dr. Goldstein and Dr. Krimsky requested 
to be recorded as voting against the motion. 
Dr. Gottesman, in noting the closeness of the vote, again offered for 
consideration her substitute proposal. Her proposal was that, if 
Dr. Fredrickson should not acc^t Dr. Brill's amended proposal, the 
sense of the RAC was that it would be preferable to the status quo to 
make at least two changes in the Guidelines; (1) to extend the current 
situation allowing clcxiing between nonpathogenic prokaryotes at P3 
containment to include ncxpathogenic lower eukaryotes, and (2) to allow 
lowering containment below P3 for individual cases in this class to be 
approved by ORDA, rather than requiring RAC review. She moved this 
proposal. Dr. Goldstein seconded. Dr. Bems moved to table discussion. 
Dr. Canpbell seconded. By a vote of eight in favor, eleven opposed and 
no abstentions, the motion to table Dr. Gottesman's substitute motion 
failed. 
Mr. Thornton then called the vote on Dr. Gottesman's motion. By a vote 
of fourteen in favor, one opposed, and three abstentions, the RAC approved 
Dr. Gottesman's motion. 
[ 40 ] 
